Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 5, Issue 2, Pages 157-162Publisher
INFORMA HEALTHCARE
DOI: 10.1586/ECP.11.76
Keywords
drug development; drug discovery; pharmacodynamics; pharmacokinetics; quantitative analysis; systems pharmacology
Categories
Ask authors/readers for more resources
In this article, drug discovery and preclinical development paradigms, as employed in today's pharmaceutical companies, are discussed. The antimalarial drug, artemisinin, is given as an example of a compound that is unlikely to be developed by a modern pharmaceutical company, yet is a safe and effective drug for the treatment of a deadly disease. It is argued that the use of prespecified charts, listing undesired properties to deselect molecules may lead to missed opportunities in bringing best-in-class medications to patients. Implementation of systems pharmacology, disease progression and pharmacokinetic/pharmacodynamic models are proposed. These models offer a superior approach in selecting the best drug candidates with the highest chance of success of entry into the market.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available